

**Amendment to the claims**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1. (Currently amended) An adjuvant composition, **comprising (A) which comprises an ionic polysaccharide component and a saponin component, wherein the saponin component comprises and (B) an immunostimulating complex that comprises (i) a saponin and (ii) a sterol.**

2.-3. (Canceled)

4. (Currently amended) **The adjuvant** ~~[[A]]~~ composition **of claim 1** according to ~~claim 2~~, wherein the ionic polysaccharide is an ionic dextran.

5. (Currently amended) **The adjuvant** ~~[[A]]~~ composition **of** according to claim 4, wherein the ionic dextran is DEAE-dextran.

6. (Currently amended) **The adjuvant** ~~[[A]]~~ composition **of claim 1** according to ~~claim 2~~, wherein the immunostimulating complex is a protein-free **immunostimulating immunostimulatory** complex.

7. (Currently amended) **The adjuvant** ~~[[A]]~~ composition **of claim 1** according to ~~claim 2~~, wherein the immunostimulating complex **further** comprises Quil A, cholesterol and a phospholipid, **and wherein the saponin is Quil A and wherein the sterol is cholesterol.**

8. (Currently amended) **The adjuvant** ~~[[A]]~~ composition **of claim 1** according to ~~claim 2~~, wherein the mass ratio of ~~the~~ ionic polysaccharide component to ~~the~~ immunostimulating complex component is in the range of 50 to 300.

9. (Currently amended) **The adjuvant** ~~[[A]]~~ composition **of** according to claim 8, wherein the mass ratio is about 125.

10. (Currently amended) The adjuvant ~~[[A]]~~ composition of claim 1 ~~according to~~ ~~claim 2~~, comprising about 10 mg DEAE-dextran of the ionic polysaccharide and about 80 µg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.

11. (Currently amended) The adjuvant ~~[[A]]~~ composition of claim 1 ~~according to~~ ~~claim 2~~, comprising about 100 mg DEAE-dextran of the ionic polysaccharide and about 800 µg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.

12. (Currently amended) The adjuvant ~~[[A]]~~ composition of claim 1 ~~according to~~ ~~claim 2~~, comprising about 150 mg DEAE-dextran of the ionic polysaccharide and about 500 µg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.

13. (Currently amended) An immunogenic composition comprising an immunogen and ~~the an~~ adjuvant composition of ~~wherein said adjuvant composition is a composition according to claim 1.~~

14. (Currently amended) ~~The An~~ immunogenic composition of ~~according to claim 13~~, wherein said immunogen comprises LHRH.

15. (Currently amended) ~~The An~~ immunogenic composition of ~~according to claim 14~~, wherein said immunogen comprises an LHRH-diphtheria toxoid conjugate.

16. (Currently amended) ~~The An~~ immunogenic composition of ~~according to claim 15~~, comprising 5-500 µg of LHRH-diphtheria toxoid conjugate, ~~in 5-500 mg of the~~ ionic polysaccharide, and 40-4000 µg of the immunostimulating complex.

17. (Currently amended) A pharmaceutical composition, comprising (i) ~~the an~~ immunogenic composition of ~~according to claim 13~~, and (ii) together with one or more pharmaceutically acceptable carriers ~~and/or diluents.~~

18. (Currently amended) A method of eliciting, ~~in an animal~~, an effective immune response in an animal, ~~said method~~ comprising administering to an ~~said~~ animal an effective amount of the ~~an~~ immunogenic composition of ~~according to~~ claim 13.

19. (Canceled)

20. (Previously presented) A composition according to claim 8, wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is in the range of 100 to 140.

21. (New) The pharmaceutical composition of claim 17, further comprising a pharmaceutically acceptable diluent.

22. (New) The method of claim 18, wherein said composition further comprises a pharmaceutically acceptable diluent.